大剂量甲氨蝶呤、表柔比星联合顺铂新辅助化疗骨肉瘤的疗效分析*

doi:10.16833/j.cnki.jbmc.2022.09.003

包头医学院学报 ›› 2022, Vol. 38 ›› Issue (9): 10-14.doi: 10.16833/j.cnki.jbmc.2022.09.003

大剂量甲氨蝶呤、表柔比星联合顺铂新辅助化疗骨肉瘤的疗效分析^*

郑家雷¹, 莫缓缓¹, 吴骁¹, 方向², 胡婷¹

1.蚌埠医学院第一附属医院肿瘤内科,安徽蚌埠 233003;
2.中国科学技术大学附属第一医院老年消化科

收稿日期:2022-01-19 出版日期:2022-09-25 发布日期:2022-09-09
通讯作者: 莫缓缓
基金资助:
* 蚌埠医学院自然科学基金重点项目(2020byzd164)

Efficacy analysis of high-dose methotrexate, epirubicin combined with cisplatin in neoadjuvant chemotherapy for osteosarcoma

ZHENG Jialei¹, MO Huanhuan¹, WU Xiao¹, FANG XIANG², HU Ting¹

1. Department of Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233003,China;
2. Department of Geriatric Gastroenterology, the First Affiliated Hospital of University of Science and Technology of China

Received:2022-01-19 Online:2022-09-25 Published:2022-09-09

摘要/Abstract

摘要： 目的:观察大剂量甲氨蝶呤(MTX)、表柔比星(EPI)联合顺铂(PDD)新辅助化疗治疗Ⅱb期骨肉瘤的疗效和不良反应。方法:分析25例经病理诊断、初治、Ⅱb期肢体骨肉瘤患者接受大剂量甲氨蝶呤(10～12 g/m²)、表柔比星(80 mg/m²)、顺铂(75 mg/m²)联合化疗的疗效和不良反应。结果:保肢成功率为76 %,5年PFS率达到72 %:5年复发转移率28 %,5年生存率72 %。最常见的不良反应为血液学毒性中性粒细胞减少、贫血、血小板下降、肝功能损害,非血液学毒性脱发、恶心呕吐、腹泻、口腔黏膜炎,多为轻到中度;Ⅲ-Ⅳ级的恶心、呕吐、中性粒细胞减少、脱发、肝功能损害发生率分别为32 %、36 %、68 %和4 %。结论:大剂量甲氨蝶呤、表柔比星、顺铂联合方案新辅助治疗Ⅱb期骨肉瘤保肢成功率高,5年生存率高、复发转移率低,疗效确切,不良反应轻,耐受性良好,值得临床推广使用。

关键词: 甲氨蝶呤, 顺铂, 表柔比星, 新辅助化疗, 骨肉瘤

Abstract: Objective: To observe the efficacy and adverse reaction of neoadjuvant chemotherapy with high-dose methotrexate (MTX), epirubicin (EPI) and cisplatin (PDD) for stage Ⅱb osteosarcoma. Methods: The efficacy and adverse reactions of high dose methotrexate ( 10-12 g/m²), epirubicin (80 mg/m²) and cisplatin (75 mg/m²) combined chemotherapy in 25 patients with pathological diagnosis, initial treatment and stage Ⅱb limb osteosarcoma were analyzed. Results: The success rate of limb salvage was 76 %, the 5-year PFS rate reached 72 %: the 5-year recurrence and metastasis rate was 28 %, and the 5-year survival rate was 72 %.The most common adverse reactions were hematological toxic neutropenia, anemia, thrombocytopenia, and liver function damage.Non-hematological toxicity was alopecia, nausea and vomiting, diarrhea, and oral mucositis, mostly mild to moderate.The incidences of grade Ⅲ-Ⅳ nausea, vomiting, neutropenia, alopecia and liver dysfunction were 32 %, 36 %, 68 % and 4 %, respectively. Conclusion: High-dose methotrexate, epirubicin and cisplatin combined with neoadjuvant therapy for stage Ⅱb osteosarcoma has high limb salvage success rate, high 5-year survival rate, low recurrence and metastasis rate, exact curative effect, mild adverse reactions and good tolerance, which is worthy of clinical promotion and use.

Key words: High-dose methotrexate, Cisplatin, Epirubicin, Neoadjuvant chemotherapy, Osteosarcoma

郑家雷, 莫缓缓, 吴骁, 方向, 胡婷. 大剂量甲氨蝶呤、表柔比星联合顺铂新辅助化疗骨肉瘤的疗效分析^*[J]. 包头医学院学报, 2022, 38(9): 10-14.

ZHENG Jialei, MO Huanhuan, WU Xiao, FANG XIANG, HU Ting. Efficacy analysis of high-dose methotrexate, epirubicin combined with cisplatin in neoadjuvant chemotherapy for osteosarcoma[J]. Journal of Baotou Medical College, 2022, 38(9): 10-14.

参考文献

[1] 张春林.多学科协作积极开展骨肉瘤患者的规范化保肢治疗[J].赣南医学院学报,2021,41(8):791-796.
[2] Endo-Munoz L,Bennettt C,Topkas E,et al.Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma[J].Vet Comp Oncol,2020,18(2):206-213.
[3] Harrisond J,Gellerd S,Gillj D,et al.Current and future therapeutic approaches for osteosarcoma[J].Expert Rev Anticancer Ther,2018,18(1):39-50.
[4] Wang W,Zhao HF,Yao TF,et al.Advanced development of ErbB family-targeted therapies in osteosarcoma treatment[J].Investig New Drugs,2019,37(1):175-183.
[5] 陈俭,李野,谢克恭.骨肉瘤肺转移相关信号通路研究进展[J].华西医学,2022,37(2):306-312.
[6] 郑家雷,方向,汪子书.大剂量甲氨蝶呤、顺铂联合阿霉素新辅助化疗骨肉瘤的近期疗效分析[J].蚌埠医学院学报,2015,40(12):1631-1634.
[7] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)经典型骨肉瘤诊疗指南2020[M].北京:人民卫生出版社,2020.
[8] Collins M,Wilhelm M,Conyers R,et al.Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma:findings from a meta-analysis[J].J Clin Oncol,2013,31(18):2303-2312.
[9] Xuh R,Huang Z,Li Y,et al.Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients:a prospective non-randomized controlled study[J].Cancer Biol Med,2019,16(1):166-172.
[10] Choua J,Kleinermane S,Krailom D,et al.Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma[J].Cancer,2009,115(22):5339-5348.
[11] 杨勇昆,徐海荣,黄真,等.聚乙二醇化脂质体多柔比星治疗骨肉瘤的有效性和安全性[J].中华肿瘤杂志,2020,42(8):692-696.
[12] Xu J,Guo W,Xie L.Combination of gemcitabine and docetaxel:a regimen overestimated in refractory metastatic osteosarcoma [J].BMC Cancer,2018,18(1):987.
[13] Kuo C,Kentp M,Logana D,et al.Docetaxel,bevacizumab,and gemcitabine for very high risk sarcomas in adolescents and young adults:asingle-center experience[J].Pediatr Blood Cancer,2017,64(4):e26265.
[14] Grignani G,Palmerini E,Dileo P,et al.A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy:an Italian Sarcoma Group study[J].Ann Oncol,2012,23(2):508-516.
[15] Grignani G,Palmerini E,Ferraresi V,et al.Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment:a non-randomised phase 2 clinical trial[J].Lancet Oncol,2015,16(1):98-107.
[16] Duffaud F,Mir O,Doudou-Rouquette P,et al.Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma:a non-comparative,randomised,double-blind,placebo-controlled,phase 2 study[J].Lancet Oncol,2019,20(1):120-133.
[17] 王文剑,于秀淳,韩加,等.1593例骨肉瘤流行病及治疗的回顾性分析[J].中华骨科杂志,2018(18):1097-1107.
[18] 左冬青,穆浩然,孙梦熊,等.中老年骨肉瘤患者化疗选择及预后的单中心五年回顾性研究[J].中国骨与关节杂志,2021,10(5):328-332.

大剂量甲氨蝶呤、表柔比星联合顺铂新辅助化疗骨肉瘤的疗效分析^*

Efficacy analysis of high-dose methotrexate, epirubicin combined with cisplatin in neoadjuvant chemotherapy for osteosarcoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价